Press-release for stocks for nvsef listed in the nyse exchange

Viral Vector and Plasmid DNA Technologies: A Global Market Perspective
Published: 2024-04-17 (Crawled : 10:00) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M

Health Technology

| 1.46% | O: -0.26% H: 0.03% C: -1.55%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 6.51% | O: 0.87% H: 0.16% C: -0.59%
RGNX | $16.05 0.94% 0.93% 350K

Health Technology

| -10.9% | O: -1.43% H: 2.27% C: -3.18%
global dna market

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 6.51% | O: 0.87% H: 0.16% C: -0.59%
kesimpta sclerosis novartis show benefits

Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 7.2M

Health Technology

| 0.35% | O: -0.53% H: 0.0% C: -1.24%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
PHG | News | $20.97 -0.19% 0.0% 650K

Health Technology

| 1.64% | O: -1.21% H: 0.0% C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M

Health Technology

| 1.83% | O: -1.19% H: 0.52% C: -0.17%
VRNA | $15.21 -2.44% -2.5% 320K

Health Technology

| -1.33% | O: 1.65% H: 2.43% C: 0.87%
reach treatment research market

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K

Health Technology

| -0.84% | O: -1.94% H: 0.43% C: -0.34%
OCUL | News | $4.645 -7.1% -7.64% 3.9M

Health Technology

| -35.4% | O: -1.03% H: 3.66% C: 1.7%
ocular key leaders

Biologic Therapeutics Market size is set to grow by USD 286.12 billion from 2023-2027, Introduction of biosimilars boost the market, Technavio
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480

Health Technology

| 1.38% | O: -1.75% H: 0.85% C: 0.85%
AZNCF | News | $140.3 -4.19% 1.5K

Health Technology

| 3.21% | O: 2.1% H: 0.0% C: -2.52%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M

Health Technology

| 1.83% | O: -1.19% H: 0.52% C: -0.17%
BAX | $40.93 -0.22% 0.0% 2.1M

Health Technology

| 2.45% | O: -0.1% H: 0.13% C: -1.08%
ABBV | News | $167.83 -1.01% 0.0% 4M

Health Technology

| 4.87% | O: 0.32% H: 0.96% C: 0.22%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 0.41% | O: -2.13% H: 0.0% C: 0.0%
BMRN | $91.25 -0.88% -0.89% 1.6M

Health Technology

| 0.6% | O: -0.72% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M

Health Technology

| 3.08% | O: -0.64% H: 0.45% C: -0.04%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 3.02% | O: 0.41% H: 0.0% C: 0.0%
set therapeutics market

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
fabhalta nephropathy for novartis show

Novartis tender offer for MorphoSys AG commences
Published: 2024-04-11 (Crawled : 09:00) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K

Health Technology

| 2.02% | O: -0.32% H: 0.48% C: -0.17%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 4.54% | O: 0.32% H: 0.04% C: -0.56%
MOR | News | $18.07 0.17% 0.17% 130K

Health Technology

| 0.25% | O: 0.69% H: 0.0% C: -0.39%
for novartis

Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio
Published: 2024-04-10 (Crawled : 09:00) - prnewswire.com
ALPMF | News | $9.5 43.47% 1.2K

Health Technology

| -11.83% | O: -100.0% H: NaN% C: Infinity%
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -0.01% | O: -0.01% H: 0.0% C: 0.0%
NVSEF | News | $96.0 6.88% 52K

Health Technology

| 0.31% | O: -1.67% H: 0.0% C: 0.0%
ALPMY | News | $9.49 -1.11% 480K

Manufacturing

| -9.36% | O: -0.29% H: 0.0% C: -1.97%
VTRS | News A | $11.55 1.67% 1.65% 7.2M

Health Technology

| -3.07% | O: -0.6% H: 1.03% C: 0.52%
TMO | News | $577.39 0.49% 0.0% 2M

Health Technology

| -4.03% | O: -2.01% H: 0.0% C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 3.33% | O: -1.16% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -0.99% | O: -0.32% H: 0.0% C: 0.0%
JAZZ | $108.38 -1.18% -1.19% 400K

Health Technology

| -5.16% | O: -1.71% H: 0.57% C: 0.37%
disorders system set market

Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480

Health Technology

| 1.68% | O: 2.24% H: 0.0% C: -0.8%
AZNCF | News | $140.3 -4.19% 1.5K

Health Technology

| 5.31% | O: -3.43% H: 6.21% C: 6.21%
VTRS | News A | $11.55 1.67% 1.65% 7.2M

Health Technology

| -3.73% | O: -0.25% H: 1.1% C: -0.17%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 3.2% | O: -0.05% H: 0.43% C: -0.27%
BMY | $48.86 -0.27% 0.0% 16M

Health Technology

| -4.54% | O: -0.08% H: 0.04% C: -0.35%
BHC | $8.56 0.35% 0.0% 2M

Health Technology

| -18.06% | O: 0.38% H: 0.0% C: -7.27%
ABBV | News | $167.83 -1.01% 0.0% 4M

Health Technology

| 0.96% | O: 0.77% H: 1.63% C: 0.35%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 0.29% | O: 0.84% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M

Health Technology

| 5.04% | O: 0.18% H: 0.3% C: 0.19%
eczema dermatitis set therapeutics market

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K

Health Technology

| Email alert Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| Email alert Add to watchlist
leqvio novartis therapy show

Positron Emission Tomography Market size is set to grow by USD 725.97 mn from 2024-2028,increasing prevalence of chronic conditions worldwide boost the market- Technavio
Published: 2024-04-03 (Crawled : 06:00) - prnewswire.com
CAJPY | $28.73 -0.41% 39K

n/a

| -2.91% | O: -0.3% H: 0.54% C: 0.54%
CAJFF | $29.0664 -28.15% 760

Electronic Technology

| -2.61% | O: -100.0% H: NaN% C: Infinity%
NVSEF | News | $96.0 6.88% 52K

Health Technology

| 1.05% | O: -2.86% H: 0.17% C: 0.17%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 4.71% | O: 0.04% H: 0.46% C: -0.08%
PHG | News | $20.97 -0.19% 0.0% 650K

Health Technology

| 5.47% | O: 1.0% H: 0.0% C: 0.0%
worldwide set market

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $21.8 1.63% 1.61% 120K

n/a

| -4.26% | O: 6.23% H: 2.77% C: -10.21%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 2.57% | O: 0.47% H: 0.23% C: -0.99%
pharma business

Carisma Therapeutics Announces Changes to its Board of Directors
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology